Observational registry data from Sweden showed a significant link between SGLT2 inhibitor use at the time of an MI in people with type 2 diabetes and fewer all-cause deaths in 1-year follow-up.
Study findings suggest that patients be screened for vitamin D deficiency before starting SGLT2 inhibitor therapy, or they should simply be prescribed vitamin D supplements.
However, an important take-home message from this new meta-analysis is that these widely used medications appeared to be safe even in acutely ill hospitalized patients, the researchers say.
Results of the DICTATE-AHF randomized trial that tested starting dapagliflozin for patients hospitalized with acute heart failure confirmed the safety and benefit of this guideline-directed strategy.